IL17A and cancer: Functionally, FoxP3+IL17A+ Tregs from sporadic CRC patients maintained their suppressive phenotype against CD4+ and CD8+ T cells [99] but they were involved in cancer initiation by targeting epithelial cells in an IL17A-dependent manner [95,100].